Advancing DART Platform Will Drive Targeted Immuno-Oncology Gains Despite Setbacks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
10 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$5.00
66.2% undervalued intrinsic discount21 Aug
US$1.69
1Y
-51.6%7D
7.0%